-
Mashup Score: 3
In a joint conference event on Monday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3AZGP1 deficiency promotes angiogenesis in prostate cancer - Journal of Translational Medicine - 7 day(s) ago
Background Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion. The exact role of AZGP1 in prostate cancer progression remains elusive. Method AZGP1 knockout and overexpressing prostate cancer cells were generated using a lentiviral system. The effects of AZGP1 under- or over-expression in prostate cancer cells were evaluated by in vitro cell proliferation, migration, and invasion assays. Heterozygous AZGP1± mice were obtained from European Mouse Mutant Archive (EMMA), and prostate tissues from homozygous knockout male mice were collected at 2, 6 and 10 months for histological analysis. In vivo xenografts generated from AZGP1 under- or over-expressing prostate cancer cells were used to determine the role of AZGP1 in prostate cancer tumor growth, and
Categories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 22
Ferroptosis regulation remains poorly understood. Rodencal et al. demonstrate that cell cycle arrest enhances sensitivity to ferroptosis when ferroptosis is induced by direct inhibition of GPX4. It may be possible to target this mechanism in vivo using growth-arresting agents together with an orally bioavailable GPX4 inhibitor.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2SCI-JEDI Seed Grant - 12 day(s) ago
A funding opportunity for individuals across the educational continuum to facilitate continued support in projects that make progress towards inclusive excellence at the Stanford Cancer Institute.
Source: med.stanford.eduCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 13
The award provides generous funding for immigrants and children of immigrants pursuing graduate degrees.
Source: news.stanford.eduCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis - 19 day(s) ago
npj Digital Medicine – Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma - PubMed - 2 month(s) ago
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although cSCC contributes to substantial morbidity and mortality in high-risk individuals, deployment of otherwise effective chemoprevention of cSCC is limited by toxicities. Our systematic computational drug repurposing …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma - 2 month(s) ago
Background:In situ vaccination for the treatment of cancer aims to trigger an immune response locally that propagates systemically. We have shown that local tre
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells - 3 month(s) ago
CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR-Cas9 genome-editing tools are limited in their safety, …
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists1Tweet
Stanford and U Penn researchers found no link between #CARTcells therapies and the development of secondary T-cell malignancies. https://t.co/dEN3YOnxGj @parkerici #CellTherapy